AVTX
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (AVTX) has 18 SEC Form 4 filings (44 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 2, 2026.
The most active filer is Chief Medical Officer Doyle Mittie with 6 filings. Insiders have net sold $5.4M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Garry A. Neil
- Employees:33
- HQ:Rockville, MD, US
- IPO:2015-10-14
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.4M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$954.1M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Medical Officer | Sale | 4,654 | $93K | Jul 2 | SEC ↗ | |
| Chief Medical Officer | Sale | 1,450 | $26K | Jun 25 | SEC ↗ | |
| Chief Medical Officer | Sale | 679 | $11K | Jun 1 | SEC ↗ | |
| Chief Medical Officer | Sale | 3,000 | $56K | May 19 | SEC ↗ | |
| Chief Financial Officer | Sale | 18,606 | $449K | May 11 | SEC ↗ | |
Doyle MittieFirst filing | Chief Medical Officer | Sale | 1,679 | $27K | May 7 | SEC ↗ |
Doyle MittieFirst filing | Chief Medical Officer | Sale | 106,555 | $2.2M | May 7 | SEC ↗ |
VARKI PAULFirst filing | Chief Legal Officer | Sale | 75,063 | $1.5M | May 7 | SEC ↗ |
Sullivan Christopher RyanFirst filing | Chief Financial Officer | Sale | 47,000 | $949K | May 7 | SEC ↗ |
Chan MitchellFirst filing | Director | Sale | 3,167 | $72K | May 7 | SEC ↗ |
Related companies
Avalo Therapeutics, Inc. is in the Healthcare sector.